May 23, 2023 03:03 PM EDT
Pharma
FDA+
Manufacturing

FDA warns Sure-BioChem over qual­i­ty and da­ta is­sues

Tyler Patchen

News Reporter

A warn­ing let­ter has been giv­en to a com­pa­ny that tests fin­ished drug prod­ucts over sev­er­al qual­i­ty is­sues.

The FDA is­sued the warn­ing

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times